Form 4: Dyne Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations

Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• On May 16, 2024, Wildon Farwell, the Chief Medical Officer of Dyne Therapeutics, sold 1,956 shares of common stock at a weighted average price of $28.2.
• He also sold 425 shares at a weighted average price of $28.59.
• These sales were to cover tax withholding obligations related to the vesting of restricted stock units granted on November 15, 2023.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan established on January 25, 2024.
• Following these transactions, Farwell beneficially owns 148,179 shares, including 119,209 unvested RSUs.

Sentiment

Score: 5

Explanation: The document describes routine transactions related to tax obligations, which is neutral in sentiment.

Industry Context

Sales of shares by company insiders are a common occurrence, often related to tax obligations or diversification strategies. The use of a pre-arranged Rule 10b5-1 trading plan suggests the sales were planned and not based on current market information.

Stakeholder Impact

• The share sales by the Chief Medical Officer could have a minor negative impact on shareholder sentiment, although the sales were pre-planned and for tax purposes.

Key Dates